1. Clinical Overview of AICAR

Molecule:
AICAR is an AMP analog and intracellular AMP-activated protein kinase (AMPK) activator. It functions as a metabolic signaling molecule that mimics a low-energy cellular state, triggering adaptive pathways involved in energy production, fat oxidation, glucose uptake, and mitochondrial biogenesis.

Classification:

AMPK activator
Metabolic signaling modulator
Exercise-mimetic compound
Mitochondrial biogenesis enhancer

Core Concept: AICAR activates many of the same intracellular pathways stimulated by exercise and caloric restriction, without directly increasing adrenergic stimulation.

2. Mechanisms of Action

2.1 AMPK Activation (Primary Mechanism)

AICAR is phosphorylated intracellularly to ZMP, an AMP mimetic that activates AMPK, the master metabolic regulator.

AMPK activation results in:

Increased glucose uptake (GLUT4 translocation)
Enhanced fatty acid oxidation
Suppression of lipogenesis
Increased mitochondrial biogenesis
Improved insulin sensitivity

Clinical Benefit: Restores metabolic flexibility and cellular energy efficiency.

2.2 Mitochondrial Biogenesis & PGC-1α Signaling

Through AMPK → PGC-1α activation, AICAR promotes:

Increased mitochondrial number
Improved oxidative phosphorylation
Enhanced endurance capacity

This pathway is central to longevity and metabolic resilience.

2.3 Exercise-Mimetic Effects

AICAR reproduces several exercise-induced adaptations:

Increased oxidative muscle fibers (Type I)
Enhanced endurance performance
Improved lactate handling
Reduced metabolic fatigue

2.4 Glucose & Lipid Metabolism

AICAR:

Enhances insulin-independent glucose uptake
Reduces hepatic gluconeogenesis
Increases fatty acid transport into mitochondria

Clinical Benefit: Improved glycemic control and fat utilization.

2.5 Anti-Inflammatory & Cytoprotective Effects

AMPK activation downregulates:

NF-κB signaling
Pro-inflammatory cytokines
Oxidative stress pathways

3. Evidence-Based Clinical Applications

Important: Human clinical use is off-label and investigational. Most data derive from animal models, cellular studies, and limited human metabolic research.

3.1 Metabolic Syndrome & Insulin Resistance

AICAR supports:

Improved insulin sensitivity
Reduced ectopic fat accumulation
Enhanced metabolic flexibility

3.2 Weight Management & Fat Oxidation

By increasing fat utilization and suppressing lipogenesis, AICAR may support:

Fat loss
Lean mass preservation
Improved metabolic rate

Often used as an adjunct, not monotherapy.

3.3 Endurance & Athletic Performance

Preclinical and early human data demonstrate:

Increased endurance capacity
Enhanced oxidative muscle phenotype
Improved recovery

This has led to WADA prohibition in competitive athletics.

3.4 Longevity & Healthy Aging

AMPK activation is strongly associated with:

Lifespan extension in model organisms
Improved cellular stress resistance
Reduced age-related metabolic decline

3.5 Mitochondrial Dysfunction & Fatigue

Potential benefit in:

Chronic fatigue patterns
Post-viral fatigue (theoretical)
Mitochondrial insufficiency states

4. Administration & Dosing Protocols

AICAR is not intended for continuous daily use long-term. Protocols are typically short cycles with defined off-periods.

4.1 Reconstitution

10 mg vial AICAR

Add:

1 mL bacteriostatic saline → 10 mg/mL
or
2 mL saline → 5 mg/mL

Gently swirl; do not shake.

4.2 Route of Administration

Subcutaneous (SC) — preferred
Intramuscular (IM) — optional

4.3 Dosing Frameworks (Clinical Use Patterns)

Metabolic Optimization / Longevity Cycle

5–10 mg SC daily
5–10 consecutive days

Cycle frequency: Every 4–8 weeks; typically 2–4 cycles per year

Fat Oxidation / Weight-Management Adjunct

5 mg SC daily × 7–10 days
Combined with nutritional and lifestyle interventions

Endurance / Mitochondrial Support (Non-Competitive Athletes)

5–10 mg SC daily × 5–7 days
Not for use in tested athletes

4.4 Post-Cycle Support

Often paired after AICAR cycles with:

L-Carnitine (LC-600)
NAD⁺ / mitochondrial support
CJC-1295 / Ipamorelin
FOXO4-DRI or other longevity peptides (non-concurrent)

5. Clinical Decision Trees

Decision Tree 1 — Candidate Selection

Insulin resistance or metabolic inflexibility? → Yes

Fat-loss plateau despite diet/exercise? → Consider

Endurance or mitochondrial support need? → Consider

Competitive athlete under WADA rules? → Do NOT use

Active malignancy? → Avoid

Decision Tree 2 — Cycle Planning

First-time use → 5 mg × 5 days

Good tolerance → 5–10 mg × 7–10 days

Longevity focus → 1–2 short cycles/year

Fat loss focus → Combine with nutrition & activity

6. Safety, Contraindications & Monitoring

6.1 Contraindications

Active malignancy
Pregnancy or breastfeeding
Severe hepatic or renal disease
Competitive athletes subject to drug testing
Hypersensitivity to compound

6.2 Potential Side Effects

Usually dose-dependent and transient:

Fatigue or lethargy during cycle
Mild nausea
Headache
Injection-site irritation
Hypoglycemia (rare; monitor in diabetics)

6.3 Monitoring Considerations

Fasting glucose / insulin
Energy and fatigue patterns
Body composition
Inflammatory markers (optional)
Adequate recovery between cycles

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

AICAR (5-Aminoimidazole-4-Carboxamide Ribonucleotide), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — AICAR (10 mg) Clinical Reference Guide

AMPK Biology & Metabolic Regulation

1. Hardie, D. G., Ross, F. A., & Hawley, S. A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 13(4), 251–262 (2012).

2. Hardie, D. G. AMP-activated protein kinase: Maintaining energy balance. Nature Reviews Endocrinology, 10(4), 197–209 (2014).

AICAR Mechanisms & Exercise-Mimetic Effects

3. Corton, J. M., Gillespie, J. G., & Hardie, D. G. AICAR activates AMPK in intact cells. European Journal of Biochemistry, 229(2), 558–565 (1995). (Foundational AICAR-AMPK paper.)

4. Narkar, V. A., et al. AMPK and PPARδ agonists are exercise mimetics. Cell, 134(3), 405–415 (2008). (Seminal endurance-enhancement study.)

Glucose & Lipid Metabolism

5. Merrill, G. F., et al. AICAR increases glucose uptake and insulin sensitivity. American Journal of Physiology — Endocrinology and Metabolism, 273(6), E1107–E1112 (1997).

6. Bergeron, R., et al. AICAR improves insulin resistance in skeletal muscle. Diabetes, 50(5), 1076–1082 (2001).

Mitochondrial Biogenesis & Longevity

7. Jäger, S., et al. AMPK regulates PGC-1α and mitochondrial biogenesis. Proceedings of the National Academy of Sciences, 104(29), 12017–12022 (2007).

8. Cantó, C., & Auwerx, J. AMPK and longevity pathways. Cell Metabolism, 19(1), 1–15 (2014).

Inflammation & Cellular Protection

9. Salminen, A., et al. AMPK signaling in inflammation and aging. Journal of Molecular Medicine, 89(7), 667–676 (2011).

10. O'Neill, L. A. J., et al. Metabolic regulation of immune responses. Nature Reviews Immunology, 16(9), 553–565 (2016).